Genkyotex - Termination of coverage
Edison Investment Research is terminating coverage on Genkyotex (GKTX). Please note you should no longer rely on any previous research or estimates...
29 Views
Genkyotex - Ready to make a dent in the fibrosis market
Genkyotex has initiated a Phase II investigator-sponsored trial in patients with Type 1 diabetes (T1D) and kidney disease (DKD). Separately, it has...
65 Views
GKT831 clinical development on track
As expected, Genkyotex has initiated enrolment in the Phase II trial of GKT831 in patients with primary biliary cholangitis (PBC) in the first...
127 Views
Targeting obNOXious fibrosis
Genkyotex is a Euronext-listed company formed by the merger of Genticel and Genkyotex focused on NOX science and its application in fibrosis and...
112 Views
Final preclinical SIIL milestone achieved
Genticel has received a milestone payment of $1.2m from the Serum Institute of India (SIIL). This is the last milestone Genticel will receive...
49 Views
No more insights